Optical coherence tomography angiography (OCTA) is an important tool for investigating vascular networks and microcirculation in living tissue. Traditional OCTA detects blood vessels via intravascular dynamic scattering signals derived from the movements of red blood cells (RBCs). However, the low hematocrit and long latency between RBCs in capillaries makes these OCTA signals discontinuous, leading to incomplete mapping of the vascular networks. OCTA imaging of microvascular circulation is particularly challenging in tumors due to the abnormally slow blood flow in angiogenic tumor vessels and strong attenuation of light by tumor tissue.
Real-time imaging of vascular networks and microcirculation in living tissue plays a crucial role in better understanding pathological conditions. 1 In particular, better characterization of tumor vasculature in vivo could provide significant prognostic value for cancer patients 2 and improved measurements of their therapeutic responses, [3] [4] [5] [6] since tumor vessels are critical sites for drug delivery, angiogenic therapy, chemotherapy, and immunotherapy. 7 The variety of imaging tools currently available for in vivo angiography can mostly be classified into two categories: macroscopic and microscopic. Macroscopic imaging tools, such as computed tomography, positron emission tomography, ultrasound imaging, and magnetic resonance imaging, provide full body penetration but lack the spatial resolution to resolve small blood vessels in tissue. 8 Microscopic imaging modalities, such as confocal and multiphoton microscopy, provide subcellular imaging resolution but have suboptimal tissue penetration depth and small fields of view, which limit their applications in clinical settings. 9 The dilemma presented by these shortcomings of microscopic and macroscopic methods calls out for the development of imaging modalities that can bridge the gap and combine high resolution with deeper penetration.
Optical coherence tomography angiography (OCTA) has emerged in recent years as one of the most powerful and clinically indispensable imaging tools thanks to its subcellular resolution, millimeter tissue penetration depth, and three-dimensional imaging capability. Traditional OCTA detects blood vessels by computing an induced optical signal variance 10, 11 of moving red blood cells (RBCs), such as the speckle intensity variance, phase variance, or complex field variance. 11 However, OCTA based on detecting these dynamic scattering signals of RBCs has several intrinsic drawbacks that compromise its sensitivity and limit its utility in skin and tumors. First, the RBC flow in capillaries is in single-file and is highly heterogeneous over time and space. [12] [13] [14] [15] At diverging bifurcations, the capillaries with lower flow rate tend to have lower hematocrit, 16 which results in long latency between RBCs and discontinuous OCTA signals. 17 Increasing the OCT B-scan repetitions can improve the OCTA sensitivity for capillaries, but significantly lengthens the image acquisition time. In some capillaries, no RBCs are present due to the ultraslow plasma flow. These capillaries are called plasma channels, 18 which cannot be detected by traditional OCTA due to the lack of dynamic scattering signals. In addition, RBCs tend to migrate away from vessel walls, leaving a cell-free layer (CFL) in microvessels. 18 This prevents OCTA from being used as a quantitative tool to accurately measure the vessel diameters. In tumor tissue, strong light attenuation makes it even more challenging to image the microvessels located in the central tumor region. To circumvent these limitations and achieve ultrahighsensitivity OCTA for skin and tumor tissues, it is highly compelling to introduce intravascular contrast agents with suitable light-scattering, hydrodynamic, and pharmacokinetic properties. 16 Gold nanoparticles are attractive candidates as OCT contrast agents due to their high refractive index sensitivity, biocompatibility, and tunable plasmonic resonance. 19 We recently reported that large gold nanorods can be used as OCT contrast agents in the first near-infrared (NIR-I) window (800-1000 nm). 20 However, very few gold nanostructures have been reported as OCT contrast agents in the second near-infrared (NIR-II) imaging window (1100-1400 nm), which has lower tissue scattering and deeper photon penetration. [21] [22] [23] [24] In the work reported here, we have demonstrated that gold nanoprisms (GNPRs) are strong scatterers of light in the NIR-II window, and employed them as OCT contrast agents in live animals for the first time. Due to their surface plasmon resonance and high scattering coefficient in the NIR-II window, 25 GNPRs significantly enhanced the dynamic scattering signals in blood vessels and drastically improved the sensitivity of OCTA for skin tissue and melanoma tumors. After administering GNPRs intravenously, 41% and 59% more microvessels were detected by OCTA in healthy mouse ear skin and melanoma tumors, respectively. No leakage of the nanoparticle-contrast agents were detected outside the blood vessels, suggesting the contrast agent-enhanced OCTA processes high specificity.
GNPRs were prepared according to the method described in Supporting Information (SI).
Electron micrographs ( Figure S1a being detected at low concentration (i.e., 100 pM). However, strong OCT signals of GNPRs were imaged in whole blood at concentrations ≥250 pM. We showed that the OCT signal of GNPRs in blood increased with concentration, and the experimental data matched well with the prediction of our physical model 26 (Figure 1d ). We calculated the detection limit of GNPRs in blood to be 206 pM at a signal-to-noise ratio of 3. The speckle variance and normalized speckle variance (NSV) signals in water and blood also grew with increasing GNPR concentrations ( Figure S3 ).
The NSV signal is calculated by dividing the raw speckle variance by the OCT amplitude in each voxel, which compensates for attenuation of light and facilitates the imaging of speckle variance signals deeper in tissue.
In the first of our in vivo experiments we incrementally injected GNPRs into the mouse tail vein that the blood vessels with only 0.25 nM GNPRs exhibited significantly greater OCT intensity than they did before injection (Figure 2l , P = 0.032). However, the increase of OCT amplitude with each injection was not significant for GNPR concentrations in blood ≥0.75 nM, which can be explained by a multi-scattering effect according to our physical model. 26 Next we investigated OCT angiograms of healthy mouse ears (Figure 3a-c) with increasing concentrations of GNPRs. We obtained the OCT angiograms by detecting the blood vessels with NSV followed by segmenting the vessels with a hybrid intensity/shape-based compounding algorithm. 27 We show both the en-face projection (Figure 3d1 Figure S6 ), which is more sensitive to slow blood flows that have only phase changes. 16 Comparable NSV signals were observed in blood vessels before and after vehicle injection, but significantly higher NSV signals can be observed in the vessels after GNPR injection ( Figure   S7a -g). The cross-section angiograms showed similar vessel quantity and comparable vessel sizes before and after vehicle injection, but a significantly higher number of capillaries (diameter <10 µm) and larger-diameter vessels can be observed after GNPR injection ( Figure S7h-n) . This improvement can be attributed to the strong dynamic scattering signals of GNPRs and their homogeneous spatial distribution across the microvascular networks, which dramatically improved the OCT sensitivity and allowed the imaging of capillaries with ultraslow flow, ultralow hematocrit, plasma channels, and CFLs. The vessel diameter maps (Figure 4j -l) and histogram (Figure 4n ) showed that the injection of vehicle slightly reduced the number of capillaries visible in the OCT angiograms without altering the number of larger-diameter vessels visible. This reduced OCTA sensitivity could be caused by decreased hematocrit in capillaries due to dilution. In contrast, after GNPR injection the angiograms of mouse ears showed significantly more capillaries, indicating GNPR-enhanced OCTA dramatically improved the detection of capillaries with low RBC dynamic scattering signals, such as plasma channels and capillaries with low hematocrit and ultraslow blood flow. We also noticed that the GNPRenhanced OCTA detected more non-capillary microvessels. This might occur because the enhanced OCTA detects CFLs, improving the detection of vessels and increasing their measured diameters. By providing strong dynamic scattering signals throughout the entire vascular network, intravascular GNPRs lead to significantly enhanced sensitivity of OCTA.
To further investigate if the OCTA signals were predominantly derived from GNPR-induced dynamic scattering, we injected vehicle and GNPRs, respectively, in two groups of mice and compared their OCT angiograms before and after sacrificing the mice ( Figure S8 ). The postsacrifice images were obtained 30 min after the mice's hearts stopped beating. For the control group, the microvascular plexuses were clearly visible on the OCT angiograms before sacrifice, both before and after vehicle injection ( Figure S8a,b) . However, only weak OCTA signals of the largest blood vessels were seen on the angiograms obtained after the mice's deaths ( Figure S8c) due to the cessation of RBC flow. For the GNPR-injected mice, the OCT angiograms showed significantly more OCTA signals of microvascular plexuses ( Figure S8d,e ), which barely decreased at 30 min after the mice's hearts stopped beating ( Figure S8f ). This result suggests the OCTA signals of the GNPR-injected mice mainly originated from the intravascular dynamic scattering of GNPRs, rather than RBCs. The absence of RBC dynamic motion has negligible influence on the GNPR-enhanced OCTA signals.
The imaging specificity of GNPR-enhanced OCTA was investigated with two-photon microscopy. The mice were intravenously injected with dextran-rhodamine followed by Alexa488-labeled GNPRs. Two-photon microscopy images of the mouse ear taken 5 min postinjection show no fluorescent signals of Alexa488-labeled GNPRs can be observed outside the blood vessels ( Figure S9 ), indicating there was no extravasation of the contrast agents and GNPR-enhanced OCTA has high specificity for imaging the microvasculature network.
To investigate how GNPR-enhanced OCTA can improve the microvascular imaging in tumors, an orthotopic B16 melanoma mouse model was used for the study (inset of Figure 5a ). The mouse ear implanted with melanoma tumors was imaged before and 5 min after injection of 0.75 nM GNPRs ( Figure S10 ). The OCT angiograms were color-coded by depth (Figure 5a-d , Movies S1 and S2). Significantly higher melanoma tumor vasculature is observed on the post-injection OCT angiogram (Figure 5b ) than the pre-injection OCT angiogram (Fig.5a, Movie S3 ). From the cross-section view, the GNPR-enhanced OCT angiogram not only shows markedly more microvasculature at the tumor-host interface (Figure 5c,d) , but also shows deeper tumor vessels in the central tumor area (arrows in Fig. 5d ), which is 600~800 µm below the skin surface. The post-injection angiogram shows more vessels at the tumor-host interfaces than in the central tumor regions, as is expected since vascular density tends to decrease as tumors grow, leading to ischemia zones inside the core tumor. 29 More accurate mapping of the tumor vascular network enables better assessment of the ischemia region, which is crucial for evaluating the response to anti-angiogenic therapy. Increased vasculature was also observed in the peritumoral tissue in the post-injection OCT angiogram. We analyzed the vascular density of the tumor and peritumoral tissue at different depths (Figure 5e ). For peritumoral tissue, the highest densities of vessels are at 170 and 260 µm beneath skin surface, which locate in the two dermis layers on the dorsal and ventral sides of the ear, respectively. The post-injection angiogram shows ~30% higher vessel densities at each of these two depths. For the melanoma tumoral tissue, 65% more vasculature are shown on the post-injection OCT angiogram compared to the pre-injection angiogram at the depth of 200 µm, which has the highest tumor vascular density. The VAVDs of peritumoral and tumor tissue increased by 28 % and 59 % respectively following the administration of GNPRs (Figure 5f ). The VAVD of the tumors was greater than that of the peritumoral tissue, which could possibly be attributed to tumor-induced angiogenesis. The higher percentage increase of tumor VAVD than peritumoral VAVD after contrast agent injection can be explained by the fact that angiogenic tumor vessels having significantly lower blood flow than the normal vessels. 29 In summary, we have shown that OCTA signals derived from dynamic scattering of RBCs alone cannot accurately depict the complete microvasculature network in skin and tumors. This traditional OCTA is compromised by the high spatial and temporal heterogeneity of RBC flow in small blood vessels (i.e., the presence of plasma channels, low hematocrit, and long latency between RBCs in capillaries). It is particularly challenging to image tumor microvasculatures not only because of the significantly lower overall blood flow in angiogenic tumor vessels compared to normal vessels, but also because of the low scattering signals from the deep tumor vessels due to strong light attenuation. We have demonstrated that the sensitivity of OCTA can be dramatically improved by injecting PEGylated GNPRs as OCT contrast agents in the NIR-II imaging window, which circumvents the limitations of traditional OCT relying on RBC scattering signals and enables better characterization of the vascular networks of skin and tumors.
The surface plasmon resonance of GNPRs synthesized in this work is 1385 nm, which will also allow them to be used as spectral contrast agents 20 
